Xiamen Halosyntech Co.

What Xiamen Halosyntech Co. does

Xiamen Halosyntech Co. (厦门海乐景生化有限公司) is a privately held Chinese pharmaceutical R&D and manufacturing company founded in 2015 and headquartered at 120 Xinyuan Road, Haicang District, Xiamen, Fujian Province. The company specializes in the synthesis, process development, and commercial supply of Active Pharmaceutical Ingredients (APIs) and intermediates, with a portfolio organized across three therapeutic pillars: liver disease drugs (HBV, HCV, NASH, HCC — including Sofosbuvir, Ledipasvir, Velpatasvir, Daclatasvir, Tenofovir alafenamide, Obeticholic acid), oncology drugs (Osimertinib, Ribociclib, Ruxolitinib, Elagolix, Anamorelin), and selected difficult/scarce molecules (Crisaborole, Amorolfine, Nebivolol, Sacubitril/Valsartan).

The company's technical platform centers on a set of specialized organic synthesis capabilities — metal-catalyzed coupling reactions, anhydrous/air-free deep cold reactions, halogenation, chiral synthesis and resolution, and peptide synthesis — supported by 3 independent laboratories, 2 API pilot workshops, and a full analytical instrument suite (DSC/TGA, GC, HPLC, LC-MS, FTIR). Approximately 40 dedicated R&D personnel, including 7 professor-level senior engineers, underpin these capabilities. Beyond API/intermediate manufacturing, Halosyntech offers a layered service stack: custom synthesis, process development and scale-up, GMP workshop design and engineering general contracting, analytical services, and drug registration/filing support including impurity studies, stability studies, and CTD DMF preparation.

The business operates a direct B2B enterprise sales model targeting large domestic and international pharmaceutical companies, with separate international and domestic trade departments, a dedicated sales email ([email protected]), and trade show presence at CPhI Shanghai, CPhI Worldwide Europe, and CPhI India. Revenue is generated through project-based custom synthesis contracts, recurring API/intermediate supply agreements, and engineering services, with quote-based pricing tied to compound complexity and project scope. No revenue, funding rounds, or institutional investors are publicly disclosed.

Name

Xiamen Halosyntech Co.

Legal name

厦门海乐景生化有限公司 (Xiamen Halosyntech Co., Ltd.)

Website

https://halosyntech.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Xiamen Halosyntech Co. is a Chinese pharmaceutical manufacturer specializing in the R&D, process development, and commercial supply of APIs, intermediates, and custom synthesis services for liver disease, oncology, and other difficult drug molecules, serving large domestic and international pharmaceutical companies via direct B2B sales.

Ownership category

akta.pro rank

Product category

Pharmaceutical API Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industries

Custom Intermediates & Advanced Intermediates Manufacturing (HLAGAHAH), Small-Molecule API Process Development & Route Scouting (HLAGAHAA), Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Active pharmaceutical ingredients
• Pharmaceutical intermediates
• Custom synthesis services
• Drug process development
• Pharmaceutical contract manufacturing

Headquarters

HQ city

Xiamen

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Custom Synthesis Services: Provides custom synthesis services for pharmaceutical companies, developing synthesis processes for new drug compounds, intermediates, and APIs on a project basis
2. API and Intermediate Sales: Manufactures and sells Active Pharmaceutical Ingredients (APIs) and drug intermediates for approved drugs including those for liver disease (HBV, HCV, NASH, HCC) and oncology treatments
3. Process Development and Production: Offers process development and scale-up manufacturing services, including GMP workshop design, production line construction, and process validation
4. Regulatory/Drug Registration Services: Provides drug registration services including impurity studies, stability studies, CTD DMF preparation, and formulation process development

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Xiamen Halosyntech Co. researches, develops, and manufactures Active Pharmaceutical Ingredients (APIs) and drug intermediates — primarily for liver disease (HBV, HCV, NASH, HCC), oncology, and other difficult-to-synthesize drugs. The company also offers custom synthesis, process development, analytical testing, drug registration support, and GMP facility engineering services to pharmaceutical companies.

Product overview

Xiamen Halosyntech Co. is a pharmaceutical R&D and manufacturing company specializing in active pharmaceutical ingredients (APIs), intermediates, and custom synthesis services. The company operates a diversified product portfolio organized across three main therapeutic areas: liver disease drugs (including Velpatasvir, Asunaprevir, Grazoprevir, Ledipasvir, Daclatasvir, Sofosbuvir, Tenofovir alafenamide, and Obeticholic acid), oncology drugs (including Ruxolitinib, Ribociclib, Osimertinib, Elagolix, and Anamorelin), and other therapeutic areas (eczema, onychomycosis, hypertension, chronic heart failure). Halosyntech also provides comprehensive services including custom synthesis, process development and manufacturing, analytical services (DSC/TGA, GC, HPLC, LC-MS, FTIR), drug registration and filing, and engineering general contracting for GMP facilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Velpatasvir and intermediates Velpatasvir is a pan-genotypic NS5A inhibitor used for hepatitis C virus (HCV) treatment. Halosyntech manufactures and supplies Velpatasvir and its intermediates.
• Asunaprevir and intermediates Asunaprevir is an NS3 protease inhibitor used for hepatitis C virus (HCV) treatment. Halosyntech manufactures and supplies Asunaprevir and its intermediates.
• Grazoprevir and intermediates Grazoprevir is an NS3/4A protease inhibitor used for hepatitis C virus (HCV) treatment in combination regimens. Halosyntech manufactures and supplies Grazoprevir and its intermediates.
• Ledipasvir and intermediates Ledipasvir is an NS5A inhibitor used for hepatitis C virus (HCV) treatment in combination with sofosbuvir. Halosyntech manufactures and supplies Ledipasvir and its intermediates.
• Daclatasvir and intermediates Daclatasvir is an NS5A inhibitor used for hepatitis C virus (HCV) treatment. Halosyntech manufactures and supplies Daclatasvir and its intermediates.
• Sofosbuvir and intermediates Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor used for hepatitis C virus (HCV) treatment. Halosyntech manufactures and supplies Sofosbuvir and its intermediates.
• Tenofovir alafenamide and intermediates Tenofovir alafenamide (TAF) is a nucleotide reverse transcriptase inhibitor used for hepatitis B virus (HBV) treatment. Halosyntech manufactures and supplies Tenofovir alafenamide and its intermediates.
• Obeticholic Acid and intermediates Obeticholic acid (OCA) is a farnesoid X receptor agonist used for primary biliary cholangitis (PBC) and non-alcoholic fatty liver disease (NASH). Halosyntech manufactures and supplies Obeticholic acid and its intermediates.
• Ruxolitinib and intermediates Ruxolitinib is a JAK inhibitor used for myelofibrosis and polycythemia vera treatment. Halosyntech manufactures and supplies Ruxolitinib and its intermediates.
• Ribociclib and intermediates Ribociclib is a CDK4/6 inhibitor used for hormone receptor-positive breast cancer treatment. Halosyntech manufactures and supplies Ribociclib and its intermediates.
• Osimertinib intermediates Osimertinib is a third-generation EGFR tyrosine kinase inhibitor used for non-small cell lung cancer (NSCLC) treatment. Halosyntech manufactures and supplies Osimertinib intermediates.
• Elagolix and intermediates Elagolix is a GnRH antagonist used for endometriosis and uterine fibroids treatment. Halosyntech manufactures and supplies Elagolix and its intermediates.
• Anamorelin and intermediates Anamorelin is a ghrelin receptor agonist used for cancer cachexia treatment. Halosyntech manufactures and supplies Anamorelin and its intermediates.
• Custom Synthesis Services Custom synthesis services for complex pharmaceutical intermediates and APIs, including difficult-to-synthesize compounds with specialized reactions such as metal-catalyzed coupling, anhydrous/anaerobic deep cold reactions, halogenation, chiral synthesis and resolution, and peptide synthesis.
• Process Development and Manufacturing Process development and manufacturing services including GMP workshop design, production line setup, process validation, scale-up manufacturing, and facility construction management.
• Analytical Services Analytical testing services including DSC/TGA, GC, HPLC, LC-MS, and FTIR for pharmaceutical compound characterization and quality control.
• Drug Registration and Filing Drug registration and filing services including impurity research, stability studies, CTD DMF preparation, and formulation process development.
• Engineering General Contracting Engineering general contracting services including GMP workshop/production line design, feasibility studies, site assessment, equipment selection, manufacturing strategy development, capacity planning, facility procurement, process validation, scale-up manufacturing, IT infrastructure, and automation upgrades.

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Collaborating Universities (Names not disclosed in text)minorStrategic or Co-development PartnerImages of university logos displayed on R&D page indicate partnerships with academic institutions for research and development collaboration. Four university logos are shown, but specific institution names are not provided in text form.

Scale indicators5 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Porton Pharma Solutions: China-based CDMO specializing in small-molecule APIs, custom synthesis and process development with global regulatory reach; directly comparable service portfolio and customer overlap with Halosyntech.
• Shanghai Medicilon: China-based preclinical CRO/CDMO offering custom synthesis, process chemistry and analytical services to global pharma; directly comparable in scope of chemistry services, though with a larger discovery-CRO business alongside manufacturing.
• PharmaBlock Sciences: Specialty Chinese provider of APIs, intermediates and building blocks with strong focus on difficult chemistry and custom synthesis; closely overlaps Halosyntech's value proposition across chiral synthesis, complex intermediates and process R&D.
• Asymchem Laboratories: Chinese CDMO and API manufacturer offering custom synthesis, process development and GMP manufacturing for small-molecule APIs — directly comparable to Halosyntech's core offering, but at substantially larger scale and with more international regulatory filings.
• Topharman: Chinese API and intermediate manufacturer focused on difficult and high-potency compounds; comparable niche positioning to Halosyntech in serving innovator and generic pharma with specialized chemistry.

Regional players

• ScinoPharm Taiwan: Taiwan-based API and contract manufacturer with global regulatory filings supplying antiviral, oncology and specialty APIs; comparable product mix to Halosyntech (including difficult synthesis), but serving from a different geographic base.

Others

• Codexis: US-listed enzyme engineering company enabling chiral and complex chemistry for API manufacturing; adjacent rather than competitive, but relevant as an enabling technology partner or competitor for difficult-chemistry work that Halosyntech performs chemically.

Broad incumbents

• WuXi AppTec (WuXi STA): Largest Chinese CRO/CDMO with integrated small-molecule API development and manufacturing, multi-site global footprint, and broad regulatory inspection record; competes with Halosyntech for outsourced pharma projects across the full lifecycle.
• Zhejiang Huahai Pharmaceutical: Established Chinese API manufacturer with global regulatory approvals (including FDA-inspected facilities) producing APIs across cardiovascular, antiviral and other categories; broader portfolio and larger scale than Halosyntech but overlapping customer base.
• Shandong Xinhua Pharmaceutical: Long-established Chinese API manufacturer with broad therapeutic coverage including antivirals; competes with Halosyntech in commodity and selected specialty APIs, but at significantly larger scale.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/Halosyntech-282593212193969/?ref=bookmarks
• LinkedInlinkedin.com/company/xiamen-halosyntech-co.-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xiamen Halosyntech Co.